Iatrogenic effects of biologics for psoriasis.
Use of the biologic agents in moderate to severe chronic plaque psoriasis has provided novel and highly efficacious treatment options. Generally less systemically toxic than more traditional agents, the risks and benefits for these agents must also be considered. We present a review of the iatrogenic effects associated with use of the biologic agents in psoriasis. Focus is placed on antitumor necrosis factor agents, because they are the most studied and commonly used agents, as well as T-cell modulators and interleukin inhibitors.
Department of Dermatology, Mount Sinai School of Medicine, New York, NY 10029, USA. marylstevenson@gmail.com
Mary L
ML
Stevenson
Mark
M
Lebwohl
D000077944:Alefacept; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D003240:Connective Tissue Diseases / Q000139:chemically induced; D006333:Heart Failure / Q000139:chemically induced; D006801:Humans; D007049:Iatrogenic Disease; D009422:Nervous System Diseases / Q000139:chemically induced; D011565:Psoriasis / Q000188:drug therapy*; D011993:Recombinant Fusion Proteins / Q000009:adverse effects; D014376:Tuberculosis / Q000139:chemically induced; D014409:Tumor Necrosis Factor-alpha / Q000009:adverse effects / Q000037:antagonists & inhibitors*; D000069549:Ustekinumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products; D011993:Recombinant Fusion Proteins; D014409:Tumor Necrosis Factor-alpha; D000077944:Alefacept; D000069549:Ustekinumab